Novartis has lost a bid to keep a generic version of its top-selling heart failure drug Entresto off the U.S. market by ...

The Philippine Press Institute (PPI) together with Novartis held a hybrid seminar-workshop for journalists entitled “Anatomy ...

With Friday’s ruling by New Jersey District Judge Zahid Quraishi, Novartis joins a growing list of pharmaceutical companies ...

The Fortune 500 Europe has a feeble share of tech companies. But its industrial giants are increasingly turning to generative ...

Novartis is paying Chengdu Baiyu Pharmaceutical $70 million to add to its crop of cancer candidates. | Novartis is paying ...

As a host of generics circle the gates, Novartis has lost another bid to waylay MSN Pharmaceuticals’ copycat of the Swiss ...

Two years after raiding the offices of Novartis, Switzerland’s Competition Commission (COMCO) has dropped its investigation ...

Novartis has terminated a phase 2 trial of its SMURF1 inhibitor LTP001 in idiopathic pulmonary fibrosis (IPF) but will ...

The Committee for Medicinal Products for Human Use adopted a positive opinion for NVS' Kisqali to help reduce the risk of recurrence in people with HR+/HER2- early breast cancer.

Novartis announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion and recommended granting marketing ...

Key Insights Novartis' significant individual investors ownership suggests that the key decisions are influenced ...